Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein
Fujikawa, K.; Kawakami, A.; Eguchi, K.
Nihon Rinsho. Japanese Journal of Clinical Medicine 65(7): 1211-1217
2007
ISSN/ISBN: 0047-1852 PMID: 17642234 Document Number: 612820
TNF is a central cytokine in the pathogenesis of rheumatoid arthritis(RA), which induces synovitis as well as joint damage. Etanercept is a recombinant human soluble TNF receptor that binds specifically to TNF receptor, and inhibits TNF receptor-mediated signaling cascade. Recent investigations have revealed successful clinical efficacy of biologics in RA including etanercept. We reviewed here the structure and efficacy of etanercept in RA according to the published evidence.
Document emailed within 1 workday
Related Documents
Zhang, Y.; Gao, K.; Han, C-mei.; Rao, C-ming.; Wang, J-zhi. 2003: Study on methods and requirements for quality control of recombinant human tumor necrosis factor receptor Fc fusion protein Yao Xue Xue Bao 38(3): 165-168Chiang, K-Yueh.; Abhyankar, S.; Bridges, K.; Godder, K.; Henslee-Downey, J.P. 2002: Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease Transplantation 73(4): 665-667
Nicod, L.P.; Isler, P.; Chicheportiche, R.; Songeon, F.; Dayer, J.M. 1996: Production of prostaglandin E2 and collagenase is inhibited by the recombinant soluble tumour necrosis factor receptor p55-human gamma 3 fusion protein at concentrations a hundred-fold lower than those decreasing T cell activation European Cytokine Network 7(4): 757-763
Maroushek Boury, N.; Bosworth, B.T.; Stabel, T.J.; Kehrli, M.E.; Taylor, M.J. 1998: Cloning and expression of porcine recombinant soluble tumor necrosis factor receptor 1 American Journal of Veterinary Research 59(10): 1317-1322
Nassonov, E.L.; Samsonov, M.Y.; Tilz, G.P.; Beketova, T.V.; Semenkova, E.N.; Baranov, A.; Wachter, H.; Fuchs, D. 1997: Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis Journal of Rheumatology 24(4): 666-670
Bialas, T.; Kolitz, J.; Levi, E.; Polivka, A.; Oez, S.; Miller, G.; Welte, K. 1988: Distinction of partially purified human natural killer cytotoxic factor from recombinant human tumor necrosis factor and recombinant human lymphotoxin Cancer Research 48(4): 891-898
Alsalameh, S.; Mattka, B.; Al-Ward, R.; Lorenz, H.M.; Manger, B.; Pfizenmaier, K.; Grell, M.; Kalden, J.R. 1999: Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor Journal of Rheumatology 26(3): 645-653
Takemura, M.; Saito, K.; Seishima, M. 2005: Soluble tumor necrosis factor receptor I, Ii Nihon Rinsho. Japanese Journal of Clinical Medicine 63(Suppl 8): 158-160
Abbruzzese, J.L.; Levin, B.; Ajani, J.A.; Faintuch, J.S.; Saks, S.; Patt, Y.Z.; Edwards, C.; Ende, K.; Gutterman, J.U. 1989: Phase i trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer Cancer Research 49(14): 4057-4061
Kownatzki, E.; Kapp, A.; Uhrich, S. 1988: Modulation of human neutrophilic granulocyte functions by recombinant human tumor necrosis factor and recombinant human lymphotoxin. Promotion of adherence, inhibition of chemotactic migration and superoxide anion release from adherent cells Clinical and Experimental Immunology 74(1): 143-148
Alekperov, R.T.; Timchenko, A.V.; Samsonov, M.I.; Guseva, N.G.; Nasonov, E.L. 2004: Level of soluble tumor necrosis factor receptor type i in patients with systemic scleroderma Terapevticheskii Arkhiv 76(5): 11-15
Hori, K.; Ehrke, M.J.; Mace, K.; Mihich, E. 1987: Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon Cancer Research 47(22): 5868-5874
Rullan, P.; Murase, J. 2009: Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy Journal of Drugs in Dermatology: Jdd 8(9): 873-876
Espevik, T.; Figari, I.S.; Ranges, G.E.; Palladino, M.A. 1988: Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1 Journal of Immunology 140(7): 2312-2316
Terlikowski, S.ła.; Sulkowska, M.; Nowak, H.F. 2002: The effect of recombinant human tumor necrosis factor-alpha on Ehrlich ascites tumor growth Journal of Environmental Pathology Toxicology and Oncology: Official Organ of the International Society for Environmental Toxicology and Cancer 21(1): 87-92
Gillies, S.D.; Wesolowski, J.S.; Lo, K.M. 1991: Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing tumor cells. Tumor-infiltrating lymphocyte/hormone receptor/recombinant antibody Journal of Immunology 146(3): 1067-1071
Winkelhake, J.L.; Stampfl, S.; Zimmerman, R.J. 1987: Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models Cancer Research 47(15): 3948-3953
Aicher, K.P.; Dupon, J.W.; White, D.L.; Aukerman, S.L.; Moseley, M.E.; Juster, R.; Rosenau, W.; Winkelhake, J.L.; Brasch, R.C. 1990: Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha Cancer Research 50(22): 7376-7381
He, S.; Huang, H. 1997: Monocyte tumor necrosis factor and tumor necrosis factor receptor expression in patients with alcoholic liver cirrhosis Zhonghua Nei Ke Za Zhi 36(8): 526-528
Yin, D.; Zhang, X.; Feng, Y. 1996: Effects of recombinant human tumor necrosis factor on the development of ascitic tumor and expression of c-erbB2 in the nude mouse models of ovarian cancer Zhonghua Fu Chan Ke Za Zhi 31(5): 291-292